May 2026—City of Hope is implementing Quest Diagnostics’ Haystack MRD, a circulating-tumor DNA minimal residual disease test, for clinical trial patients with solid tumor cancers to help guide disease management for breast, colorectal, ovarian, and prostate cancer. The trials are investigating Haystack MRD across patient management settings, including neoadjuvant, adjuvant, and post-treatment surveillance. The multiyear research program is expected to serve about 500 patients with thousands of longitudinal measurements from 14 City of Hope sites across the country, including the Los Angeles, Orange County, Chicago, Phoenix, and Atlanta areas.
Quest Diagnostics, 800-222-0446